3-methylthiopropionyl L-carnitine and its pharmacologically acceptable salts are active on the cardiovascular system, particularly in the treatment of myocardial anoxia, cardiac ischaemia, arrhythmias and congestive heart failure.
Compositions containing (a) L-carnitine, an acyl L-carnitine, or a pharmacologically acceptable salt thereof in combination with (b) an ACE-inhibitor are useful for treating cardiovascular disorders. Orally, parenterally, rectally or transdermally administrable pharmaceutical compositions in unit dosage form contain from about 0.5 to about 2 g of L-carnitine, or an equimolar amount of an acyl L-carnitine or a pharmacologically acceptable salt thereof, and, e.g., from about 5 to about 20 mg of the ACE-inhibitor lisinopril.
The coordinated therapeutic use of L-carnitine, lower alkanoyl L-carnitines or the pharmacologically acceptable salts thereof with resveratrol, resveratrol derivatives or resveratrol-containing natural products is disclosed for producing a medicament for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy.
A therapeutical method is disclosed for treating idiopathic asthenozoospermia which comprises orally or parenterally administering to a patient in need thereof a combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in substantially equimolar amouts.
A novel therapeutical use of L-carnitine, acyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed for the treatment of non-insulin-dependent patients with a view to enhancing their peripheral glucose utilization.
A medical food for diabetics is disclosed which comprises as characterizing active ingredients .gamma.-linolenic acid and at least one alkanoyl-L-carnitine, e.g. acetyl-L-carnitine and/or propionyl-L-carnitine.
